. 2020 Sep 11;3(1):101–108. doi: 10.1016/j.cjco.2020.09.005

Table 1.

Summary of the included studies

Study	Year of study	Study location/sites	Design	Comparison	Outcomes	Mean treatment duration (wk)
Mehta et al.⁷	2011	USA, single centre	Randomized, double blind, placebo-controlled crossover trial	Ranolazine (500-1000 mg BID) vs placebo	(1) SAQ score; (2) DASI; (3) percentage of ischemic myocardium and MPRI	4
Villano et al.⁸	2013	Italy, single centre	Randomized, double blind, placebo-controlled trial	Ranolazine (375 mg BID) vs ivabradine (5 mg BID) vs placebo BID	(1) SAQ score; (2) EuroQoL scale; (3) exercise stress test; (4) FMD/NMD; (5) CFR (assessed by transthoracic Doppler echocardiography)	4
Tagliamonte et al.⁹	2015	Italy, single centre	Randomized, double blind, placebo-controlled trial	Ranolazine (500 mg BID) vs placebo BID	(1) SAQ score; (2) CFR (assessed by transthoracic Doppler echocardiography); (3) left ventricular systolic fraction assessed by echocardiography	8
Bairey Merz et al.¹⁰	2016	USA, multicentre	Randomized, double-blind, placebo-controlled, crossover trial	Ranolazine (500-1000 mg) vs placebo BID	(1) SAQ score; (2) angina diary, DASI, and general quality of life (QoL); (3) stress MPRI assessed by CMR; (4) diastolic filling assessed by CMR.	2
Safdar et al.²³	2017	USA, single centre	Randomized, double blind trial	Ranolazine (500-1000 mg) BID vs placebo	(1) CFR assessed by attenuation corrected PET imaging	4
Shah et al.¹²	2017	USA, single centre	Randomized, double-blind, placebo-controlled, crossover trial	Ranolazine (500-1000 mg) vs placebo BID	(1) CFR assessed by attenuation corrected PET imaging	4

BID, twice a day; CFR, coronary arterial flow reserve; CMR, cardiac magnetic resonance tomography; DASI, Duke Activity Status Index; EuroQoL, European quality of life visual analog scale; FMD, peripheral flow–mediated dilation; MPRI, quantitative myocardial perfusion reserve index; NMD, nitrate-mediated dilatation; PET, positron emission tomography; SAQ, Seattle Angina Questionnaire.